Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a sell rating to a hold rating in a research note released on Saturday, February 10th.

Several other equities analysts have also recently weighed in on AMPH. Piper Jaffray Companies reaffirmed a buy rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Jefferies Group set a $19.00 price target on Amphastar Pharmaceuticals and gave the company a buy rating in a report on Sunday, October 29th. Needham & Company LLC lifted their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a buy rating in a report on Friday, December 1st. BMO Capital Markets lifted their price target on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a market perform rating in a report on Friday, November 10th. Finally, Zacks Investment Research upgraded Amphastar Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $20.83.

Amphastar Pharmaceuticals (AMPH) opened at $18.78 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $19.95. The firm has a market capitalization of $874.92, a PE ratio of 126.87, a P/E/G ratio of 1.34 and a beta of 1.51.

In other news, Director Stephen B. Shohet sold 7,862 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $18.94, for a total transaction of $148,906.28. Following the sale, the director now directly owns 31,978 shares in the company, valued at $605,663.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Jason B. Shandell sold 8,661 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $19.26, for a total value of $166,810.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,058 shares of company stock valued at $1,283,317. Corporate insiders own 11.10% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Amphastar Pharmaceuticals by 10.8% in the second quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock valued at $43,128,000 after acquiring an additional 235,033 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Amphastar Pharmaceuticals by 17.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after purchasing an additional 226,271 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Amphastar Pharmaceuticals by 2.0% during the second quarter. Northern Trust Corp now owns 485,706 shares of the company’s stock worth $8,675,000 after purchasing an additional 9,672 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 332,824 shares of the company’s stock worth $6,403,000 after purchasing an additional 5,435 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 1,746.9% during the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock worth $5,650,000 after purchasing an additional 277,771 shares during the last quarter. Hedge funds and other institutional investors own 43.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Upgraded by BidaskClub” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/17/amphastar-pharmaceuticals-amph-lifted-to-hold-at-bidaskclub.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply